Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Michael Bonelli; Daniel Mrak; Selma Tobudic; Daniela Sieghart; Maximilian Koblischke; Peter Mandl; Barbara Kornek; Elisabeth Simader; Helga Radner; Thomas Perkmann; Helmuth Haslacher; Margareta Mayer; Philipp Hofer; Kurt Redlich; Emma Husar-Memmer; Ruth Fritsch-Stork; Renate Thalhammer; Karin Stiasny; Stefan Winkler; Josef S Smolen; Judith H Aberle; Markus Zeitlinger; Leonhard X Heinz; Daniel Aletaha

doi:10.1136/annrheumdis-2021-221558

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

PDF +
Supplementary
Material

Epidemiology

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Free

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password